Logo
x

Search category

Subscribe Now

NMPA

Sobi’s Gamifant (emapalumab) Received Recommendation for Approval in China from CDE to Treat Adult and Paediatric Patients with Primary Haemophagocytic Lymphohistiocytosis

Sobi’s Gamifant (emapalumab) Received Recommendation for Approval in China from CDE to Treat Adult and Paediatric Patients with Pr...

  • February 28, 2022
Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

  • November 19, 2021
Antengene's Receives NMPA's IND Approval for P-Ib MATCH Study of ATG-008 (onatasertib) ATG-010 (selinexor) to Treat Diffuse Large B-Cell Lymphoma

Antengene's Receives NMPA's IND Approval for P-Ib MATCH Study of ATG-008 (onatasertib) ATG-010 (selinexor) to Treat Diffuse Large...

  • November 2, 2021
Everest's SPR206 Receives the NMPA's IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections

Everest's SPR206 Receives the NMPA's IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections

  • September 24, 2021
Innovent Reports NMPA's Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

Innovent Reports NMPA's Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

  • September 23, 2021
BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab (BGB-A317) to Treat Nasopharyngeal Cancer in China

BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab (BGB-A317) to Treat Nasopharyngeal Cancer in China

  • August 23, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.